Unknown

Dataset Information

0

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.

ABSTRACT: [Figure: see text].

SUBMITTER: Corbett KS 

PROVIDER: S-EPMC8449013 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.

Corbett Kizzmekia S KS   Nason Martha C MC   Flach Britta B   Gagne Matthew M   O'Connell Sarah S   Johnston Timothy S TS   Shah Shruti N SN   Edara Venkata Viswanadh VV   Floyd Katharine K   Lai Lilin L   McDanal Charlene C   Francica Joseph R JR   Flynn Barbara B   Wu Kai K   Choi Angela A   Koch Matthew M   Abiona Olubukola M OM   Werner Anne P AP   Moliva Juan I JI   Andrew Shayne F SF   Donaldson Mitzi M MM   Fintzi Jonathan J   Flebbe Dillon R DR   Lamb Evan E   Noe Amy T AT   Nurmukhambetova Saule T ST   Provost Samantha J SJ   Cook Anthony A   Dodson Alan A   Faudree Andrew A   Greenhouse Jack J   Kar Swagata S   Pessaint Laurent L   Porto Maciel M   Steingrebe Katelyn K   Valentin Daniel D   Zouantcha Serge S   Bock Kevin W KW   Minai Mahnaz M   Nagata Bianca M BM   van de Wetering Renee R   Boyoglu-Barnum Seyhan S   Leung Kwanyee K   Shi Wei W   Yang Eun Sung ES   Zhang Yi Y   Todd John-Paul M JM   Wang Lingshu L   Alvarado Gabriela S GS   Andersen Hanne H   Foulds Kathryn E KE   Edwards Darin K DK   Mascola John R JR   Moore Ian N IN   Lewis Mark G MG   Carfi Andrea A   Montefiori David D   Suthar Mehul S MS   McDermott Adrian A   Roederer Mario M   Sullivan Nancy J NJ   Douek Daniel C DC   Graham Barney S BS   Seder Robert A RA  

Science (New York, N.Y.) 20210917 6561

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 μg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. mRNA-1273 vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs after SARS-CoV-2 challenge in vaccinated  ...[more]

Similar Datasets

Unknown Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
| S-EPMC7449230 | biostudies-literature
Unknown mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
| S-EPMC8488000 | biostudies-literature
Unknown mRNA-1273 vaccination protects against SARS-CoV-2-elicited lung inflammation in nonhuman primates.
| S-EPMC9310526 | biostudies-literature
Unknown Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
| S-EPMC7966917 | biostudies-literature
Unknown Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial.
| S-EPMC9178430 | biostudies-literature
Unknown Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
| S-EPMC7944952 | biostudies-literature
Unknown Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
| S-EPMC8691522 | biostudies-literature
Unknown Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.
| S-EPMC8809505 | biostudies-literature
Unknown Correlates of Vaccine-Induced Protection against SARS-CoV-2.
| S-EPMC8035658 | biostudies-literature
Unknown Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates.
| S-EPMC7265689 | biostudies-literature